48 related articles for article (PubMed ID: 28005721)
1. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
Vo TA; Abedi S; Schneider K; Chwa M; Kenney MC
Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
[TBL] [Abstract][Full Text] [Related]
2. Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera.
Giannos SA; Kraft ER; Zhao ZY; Merkley KH; Cai J
Pharm Res; 2018 Mar; 35(6):110. PubMed ID: 29600470
[TBL] [Abstract][Full Text] [Related]
3. In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs.
Cáceres-Del-Carpio J; Moustafa MT; Toledo-Corral J; Hamid MA; Atilano SR; Schneider K; Fukuhara PS; Costa RD; Norman JL; Malik D; Chwa M; Boyer DS; Limb GA; Kenney MC; Kuppermann BD
Exp Eye Res; 2020 Feb; 191():107903. PubMed ID: 31904361
[No Abstract] [Full Text] [Related]
4. Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells.
Matsuda M; da Silva RA; Roda VMP; Marquezini MV; Monteiro MLR; Hamassaki DE
PLoS One; 2024; 19(3):e0300370. PubMed ID: 38536827
[TBL] [Abstract][Full Text] [Related]
5. The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model.
Ates C; Dilbaz B; Ergani SY; Atabay F
Cir Cir; 2024; 92(1):10-19. PubMed ID: 38537244
[TBL] [Abstract][Full Text] [Related]
6. A Microfluidic Platform for the Time-Resolved Interrogation of Polarized Retinal Pigment Epithelial Cells.
Spivey EC; Yin J; Chaum E; Wikswo JP
Transl Vis Sci Technol; 2023 Nov; 12(11):28. PubMed ID: 38010283
[TBL] [Abstract][Full Text] [Related]
7. Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.
Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH
J Oncol; 2012; 2012():540791. PubMed ID: 21961001
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema.
Ferris FL; Maguire MG; Glassman AR; Ying GS; Martin DF
JAMA Ophthalmol; 2017 Feb; 135(2):145-149. PubMed ID: 28006042
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
Wykoff CC; Marcus DM; Midena E; Korobelnik JF; Saroj N; Gibson A; Vitti R; Berliner AJ; Williams Liu Z; Zeitz O; Metzig C; Schmelter T; Heier JS
JAMA Ophthalmol; 2017 Feb; 135(2):107-114. PubMed ID: 28006063
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.
Fouda SM; Bahgat AM
Clin Ophthalmol; 2017; 11():567-571. PubMed ID: 28356711
[TBL] [Abstract][Full Text] [Related]
11. RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION.
Hata M; Yamashiro K; Oishi A; Ooto S; Tamura H; Miyata M; Ueda-Arakawa N; Kuroda Y; Takahashi A; Tsujikawa A; Yoshimura N
Retina; 2017 Nov; 37(11):2069-2077. PubMed ID: 28085772
[TBL] [Abstract][Full Text] [Related]
12. Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography.
Xu D; Dávila JP; Rahimi M; Rebhun CB; Alibhai AY; Waheed NK; Sarraf D
Am J Ophthalmol; 2018 Mar; 187():10-20. PubMed ID: 29269100
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
14. Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.
Merz PR; Röckel N; Ballikaya S; Auffarth GU; Schmack I
BMC Ophthalmol; 2018 Dec; 18(1):316. PubMed ID: 30537942
[TBL] [Abstract][Full Text] [Related]
15. A Role for βA3/A1-Crystallin in Type 2 EMT of RPE Cells Occurring in Dry Age-Related Macular Degeneration.
Ghosh S; Shang P; Terasaki H; Stepicheva N; Hose S; Yazdankhah M; Weiss J; Sakamoto T; Bhutto IA; Xia S; Zigler JS; Kannan R; Qian J; Handa JT; Sinha D
Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD104-AMD113. PubMed ID: 30098172
[TBL] [Abstract][Full Text] [Related]
16. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
18. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
Chae JB; Rho CR; Shin JA; Lyu J; Kang S
Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
[TBL] [Abstract][Full Text] [Related]
19. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
